| Literature DB >> 18764943 |
Bernard Cosyns1, Steven Droogmans, Sophie Hernot, Céline Degaillier, Christian Garbar, Caroline Weytjens, Bram Roosens, Danny Schoors, Tony Lahoutte, Philippe R Franken, Guy Van Camp.
Abstract
UNLABELLED: The role of structural and functional abnormalities of small vessels in diabetes cardiomyopathy remains unclear. Myocardial contrast echocardiography allows the quantification of myocardial blood flow at rest and during dipyridamole infusion. The aim of the study was to determine the myocardial blood flow reserve in normal rats compared with streptozotocin-induced diabetic rats using contrast echocardiography.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18764943 PMCID: PMC2546381 DOI: 10.1186/1475-2840-7-26
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Figure 1Example of quantitative perfusion analysis. The rBV was quantitatively estimated by the division of myocardial plateau video intensity and the adjacent left ventricular intensity in the near wall cavity at rest and during hyperaemia (DIP).
Figure 2Histological characteristics and analysis of the myocardium in the diabetic and control rats after 20 weeks. Top panel (A), Masson's trichrome staining showed no evidence of myocardial fibrosis in both groups. Cardiomyocytes were smaller in the diabetic animals (upper right). Lower panel (B), the histological photographs (A) were subsequently converted to 8-bit grey scale images (not shown) and an appropriate threshold was chosen in order to visualize the capillaries only (black and white images, B). The percentage capillary area and capillary diameters were lower in the diabetic rats compared to controls (lower right). Magnification at 400× (A and B), scale bar is 100 μm, *P < 0.05.
Glucometry and gravimetric data obtained at 6 months of diabetes
| Controls (n = 20) | 95 ± 13 | 662 ± 49 | 1369 ± 222 | 2.1 ± 0.2 |
| Diabetics (n = 20) | 426 ± 54* | 382 ± 34* | 1182 ± 279 | 2.8 ± 0.3* |
*p < 0.05
Haemodynamic and perfusion data at baseline and during hyperaemia in controls and diabetics.
| Baseline | Hyperemia | |||||
| Variable | Controls | Diabetics | p | Controls | Diabetics | p |
| Heart rate, min-1 | 318 ± 27 | 299 ± 33 | NS | 315 ± 29 | 316 ± 25 | NS |
| SBP, mm Hg | 131 ± 7 | 131 ± 13 | NS | 96 ± 3 | 100 ± 6 | NS |
| RPP, min-1 mm Hg | 41,342 ± 1,234 | 39,056 ± 1,324 | NS | 31,339 ± 1,567 | 31,561 ± 1,234 | NS |
| MBF, ml·min -1·g -1 | 2.42 ± 0.823 | 3.75 ± 0.943 | NS | 5.81 ± 0.99 | 5.02 ± 0.76 | NS |
| β, min-1 | 23.3 ± 8.2 | 27.6 ± 9.1 | † | 32.3 ± 7.7 | 37.4 ± 9.9 | † |
| rBV, ml·min -1 | 0.112 ± 0.045 | 0.120 ± 0.05 | NS | 0.191 ± 0.046 | 0.141 ± 0.043 | * |
Values are mean ± SD. *p = 0.0001; †p = 0.005.
MBF = myocardial blood flow; rBV = relative blood volume;
RPP = rate-pressure product; SBP = systolic blood pressure.
Changes in perfusion parameters and myocardial perfusion reserve with hyperaemia
| Changes with Hyperaemia | |||
| Variable | Controls | Diabetics | p |
| MBF, ml·min-1·g -1 | 3.09 ± 0.98 | 1.28 ± 0.67 | † |
| β, min-1 | 9.1 ± 1.2 | 9.5 ± 1.1 | 0.06 |
| rBV, ml·ml-1 | 0.073 ± 0.015 | 0.023 ± 0.009 | * |
| MPR | 2.39 ± 0.89 | 1.38 ± 0.43 | † |
Values are mean ± SD. *p = 0.0001;
†p = 0.005. MBF = myocardial blood flow; rBV = relative blood volume; MPR = myocardial perfusion reserve
Figure 3Bland-Altman graphs for top (A) and slope (β) at rest and after dypiridamole in normal rats. All measurements are within 2 SD of their differences demonstrating the agreement between the two independent observers.
M-Mode parameters of the LV (parasternal short-axis view) measured in normal (n = 20) and diabetic rats (n = 20) after six months at rest and after dypiridamole infusion (DIP).
| Normal Rest | Diabetes Rest | Normal DIP | Diabetes DIP | |
| Anterior wall diastole (cm) | 0.21 ± 0.04 | 0.19 ± 0.04 | 0.21 ± 0.02 | 0.19 ± 0.02 |
| Inferior wall diastole (cm) | 0.21 ± 0.03 | 0.14 ± 0.03* | 0.2 ± 0.02 | 0.18 ± 0.02 |
| Anterior wall thickening (%) | 49 ± 17 | 47 ± 15 | 58 ± 16 | 56 ± 16 |
| Inferior wall thickening (%) | 48 ± 16 | 46 ± 14 | 48 ± 12 | 49 ± 17 |
| LV enddiastolic diameter (cm) | 0.83 ± 0.09 | 0.88 ± 0.05 | 0.81 ± 0.07 | 0.85 ± 0.05 |
| LV endsystolic diameter (cm) | 0.47 ± 0.08 | 0.52 ± 0.05 | 0.48 ± 0.06 | 0.51 ± 0.05 |
| LV enddiastolic volume (ml) | 1.24 ± 0.3 | 1.49 ± 0.2 | 1.12 ± 0.3 | 1.30 ± 0.22 |
| LV endsystolic volume (ml) | 0.29 ± 0.12 | 0.34 ± 0.08 | 0.24 ± 0.08 | 0.28 ± 0.06 |
| Fractional shortening (%) | 41.42 ± 4.40 | 41.19 ± 3.92 | 40.4 ± 2.94 | 40.47 ± 3.48 |
| LV ejectionfraction (%) | 75.22 ± 4.93 | 74.86 ± 4.21 | 78.69 ± 3.01 | 78.71 ± 3.41 |
| Left ventricular mass (g) | 1.35 ± 0.21 | 1.22 ± 0.28 | 1.34 ± 0.17 | 1.23 ± 0.22 |
* indicates p < 0.05